NBIXNBIXHealthcare · Drug Manufacturers - Specialty & Generic

NBIX Stock Forecast: Neurocrine Biosciences, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$163
−1.84% on the day

The 28 Wall Street analysts covering Neurocrine Biosciences, Inc. hold a median 12-month price target of $215 — +32.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 17 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$16.8B
Ticker Nerd rank
96/ 100
Median analyst target
$215
Analysts covering
28
Revenue$959.0M+39.5% y/y
Operating income$153.0M
Net income$144.4M
Free cash flow$128.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.6%
1M
+20.0%
YTD
+14.8%
1Y
+17.5%
From 52W high
−12.2%
From 52W low
+32.3%
$123
$186
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NBIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neurocrine Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
96/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Volatility
97
Quality
97
Growth
90
Revisions
82
Issuance
75
Momentum
68
Accruals
43
Size
11

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (43): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (11): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NBIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NBIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250Jan 26Apr 26Jul 26Oct 26NBIXHigh $253Median $215Low $150

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
24 Buy4 Hold0 Sell
Low $150Median $215High $253

The green dot is the last close — the median target sits +32.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
13 Nov 2026Morgan StanleyMaintainsEqual-Weight$185 → $191
4 Nov 2026GuggenheimMaintainsBuy$207 → $224
4 Nov 2026GuggenheimMaintainsBuy—
3 Nov 2026Canaccord GenuityMaintainsBuy$210 → $220
3 Nov 2026Canaccord GenuityMaintainsBuy—
3 Nov 2026Morgan StanleyMaintainsEqual-Weight$183 → $185
3 Nov 2026Morgan StanleyMaintainsEqual-Weight—
3 Nov 2026Piper SandlerMaintainsOverweight—
3 Nov 2026Piper SandlerMaintainsOverweight$210 → $215
3 Nov 2026RBC CapitalMaintainsOutperform—
3 Nov 2026RBC CapitalMaintainsOutperform$187 → $190
16 Oct 2026NeedhamReiteratesBuy—
16 Oct 2026NeedhamReiteratesBuy$204
12 Oct 2026BMO CapitalMaintainsMarket Perform$164 → $150
12 Oct 2026BMO CapitalMaintainsMarket Perform—
6 Oct 2026GuggenheimAssumesBuy$207
29 Sept 2026UBSMaintainsBuy$231 → $214
29 Sept 2026UBSMaintainsBuy—
11 Sept 2026Morgan StanleyMaintainsEqual-Weight$182 → $183
11 Sept 2026Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NBIX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NBIX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Neurocrine Biosciences, Inc. returned +17.5% against +12.2% for the S&P 500, dividends included.

NBIX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Jan 26Apr 26Jul 26Oct 26NBIXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NBIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+4.1%
Analysts raising
8
Analysts cutting
2
Fundamentals

Neurocrine Biosciences, Inc. (NBIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
24.6×

Cheaper than 30% of US stocks

Price / sales
4.5×

Cheaper than 25% of US stocks

Price / book
4.3×

Cheaper than 21% of US stocks

EV / EBITDA
15.4×

Cheaper than 22% of US stocks

Growth & margins
Revenue growth (YoY)
41.2%

Higher than 83% of US stocks

Earnings growth (YoY)
−1.4%

Higher than 35% of US stocks

Gross margin
97.6%

Higher than 99% of US stocks

Operating margin
26.6%

Higher than 86% of US stocks

Net margin
19.0%

Higher than 81% of US stocks

Returns & dividend
Return on equity
20.4%

Higher than 81% of US stocks

Return on assets
12.5%

Higher than 95% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Neurocrine Biosciences, Inc. (NBIX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neurocrine Biosciences, Inc. has a market value of $16.8B and an enterprise value of $16.5B.

  • Revenue in the twelve months to 30 June 2026: $3.4B. The latest quarter grew 41.2% year on year.

  • Net income over the same four quarters: $705.5M, a 20.9% net margin.

  • Diluted earnings per share, trailing twelve months: $6.82.

  • Free cash flow in the twelve months to 30 June 2026: $870.4M, after $27.7M of capital spending.

  • Neurocrine Biosciences, Inc. spent $66.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 101.6M.

  • Trailing P/E: 24.6×; forward P/E: 13.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Neurocrine Biosciences, Inc. employs 2,500 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

NBIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
NBIXNeurocrine Biosciences, Inc.$16.8B96
ELANElanco Animal Health, Inc.$12.9B97
VTRSViatris, Inc.$23.6B100
UTHRUnited Therapeutics Corp.$24.8B79
ZTSZoetis, Inc.$34.5B64
ALKSAlkermes Plc$7.5B70
AMRXAmneal Pharmaceuticals, Inc.$7.4B83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neurocrine Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NBIX news & analysis

Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term

Zacks Investment Research · 16 Nov 2026positive

Zacks Investment Research describes its Style Scores as a way for investors to find stocks it rates highly based on investing style, and presents NBIX as a long-term growth stock.

Why it matters — NBIX watchers may note the article’s favorable long-term growth framing and its focus on Zacks’ stock-rating approach.

NBIX or GRDN: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 10 Nov 2026neutral

Zacks Investment Research compares Neurocrine Biosciences and Guardian Pharmacy Services, asking which stock offers the better value opportunity. The excerpt does not provide a conclusion.

Why it matters — NBIX watchers may find the comparison relevant when reviewing the company’s valuation against another Medical - Drugs stock.

Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

PRNewsWire · 10 Nov 2026neutral

Neurocrine Biosciences said its executives will participate in the 2026 Jefferies Global Healthcare Conference in London. The presentation is scheduled for 3:30 p.m. Greenwich Mean Time on Nov. 10, 2026.

Why it matters — NBIX watchers may note the company’s scheduled participation in a healthcare investor conference.

FAQ

Frequently asked questions about NBIX stock

What is the NBIX stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Neurocrine Biosciences, Inc. have a median 12-month price target of $215, with estimates ranging from $150 to $253. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NBIX stock a buy right now?

Of the 28 analysts covering Neurocrine Biosciences, Inc., 24 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurocrine Biosciences, Inc. 96 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NBIX?

As at 17 Nov 2026, Neurocrine Biosciences, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will NBIX stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +32.0% from the last close, and Ticker Nerd's factor model ranks Neurocrine Biosciences, Inc. 96 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NBIX stock forecast for 2030?

No analyst covering Neurocrine Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NBIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $150 to $253 over the next 12 months.

How has NBIX stock performed over the past year?

Neurocrine Biosciences, Inc. returned +17.5% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neurocrine Biosciences, Inc. do?

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders.

What is the latest news on NBIX?

The most recent item we track (Seeking Alpha, 17 Nov 2026): "Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies Global Healthcare Conference 2026 Transcript". Neurocrine Biosciences presented at the Jefferies Global Healthcare Conference 2026, according to a Seeking Alpha transcript.

Company

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its current portfolio includes treatments for movement disorders such as tardive dyskinesia and Huntington’s disease chorea, as well as therapies for endocrine conditions including congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company also maintains a clinical-stage pipeline spanning additional neuroscience and endocrine targets, with research programs aimed at addressing underserved patient populations. Neurocrine Biosciences, Inc. plays an important role in specialty pharmaceuticals by combining marketed products with ongoing drug development across complex, chronic conditions that often require long-term management. Headquartered in San Diego, California, it serves patients and healthcare providers in the United States and internationally through its commercial operations and development activities.

CEO Mr. Kyle W. Gano Ph.D. · 2,500 employees · United States · https://www.neurocrine.com